RSS

multiple sclerosis (MS)

Research performed by the Cleveland Clinic has shown that the drug ibudilast slowed brain shrinkage in progressive multiple sclerosis (MS) by nearly half. more

News

Sanofi Genzyme — specialty care global business unit of French pharma company Sanofi — has launched its multiple sclerosis (MS) drug in India, however, according to GlobalData, it should be cautious of fierce generic competition… more

News

A treatment for relapsing multiple sclerosis (Gilenya — fingolimod) has been approved for use in children and adolescents aged 10 years and older by the US Food and Drug Administration (FDA). more

News

Biogen and AbbVie have announced the voluntary global withdrawal of Zinbryta (daclizumab) — a treatment for relapsing multiple sclerosis (MS) — in the best interests of patient safety. more

News

A collaboration between healthcare solutions provider, Novartis, and Pear Therapeutics has been announced that aims to develop digital therapeutics for patients with schizophrenia and multiple sclerosis (MS). more

Technology

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The Scottish Medicines Consortium (SMC) has issued its final advice, recommending restricted use of cladribine tablets (Mavenclad, Merck) for the treatment of highly active relapsing multiple sclerosis (MS). more

News

Sanofi and Principia Biopharma have entered into an agreement to develop a clinical-stage oral drug candidate as a potential therapy for multiple sclerosis (MS) and other central nervous system (CNS) diseases. more

News

Patients in England will now have immediate access to the new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad), thanks to a commercial agreement between the manufacturer, Merck, and NHS England that has been announced today. more

News

Global pharmaceutical company, Mylan, has announced that its partner Synthon has received European marketing authorisation approval for its generic, Glatiramer Acetate injection, to treat patients with relapsing forms of multiple sclerosis (MS). more

News

Science and technology company, Merck, has announced the availability of Mavenclad (cladribine tablets) in the UK and Ireland for the treatment of adults with highly active relapsing multiple sclerosis (MS). more

News

Merck has announced that the CHMP of the EMA has issued a positive opinion for approval of Cladribine tablets for the treatment of relapsing forms of multiple sclerosis (RMS) in patients with high disease activity. more

News

A quick review of some recent treatment approvals, clinical studies and general news in curing diseases, affecting patients from top to bottom. more

News

The cheap anti-cholesterol drug group, statins, are going to be used in a six-year trial to establish whether they can slow the progression of multiple sclerosis (MS). more

News

Diagnostics company, numares, and Oxford University are collaborating to develop and in-vitro diagnostic (IVD) test to improve therapeutic decision making for patients with multiple sclerosis (MS). more

News

A new drug, which has shown promise in treating multiple sclerosis is being reviewed for use in the US and Europe. more

News

A new method using a temporary drug tattoo could soon be available to help control chronic diseases like multiple sclerosis. more

News

Genentech’s phase III studies of ocrelizumab in people with relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) show positive results more

News

Novartis has acquired all remaining rights to GlaxoSmithKline’s (GSK) Ofatumumab more

News

A partnership and co-investment for the manufacturing of pharmaceutical grade D-Biotin has been announced by biotech company MedDay and nutritional solutions expert DSM Nutritional Products. more

News